Physician profile
Alejandro Leon
NPI 1104019645
$1,417.32
in general payments reported to CMS, 2019-2025
11 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2021: $250 · 2022: $82.95 · 2023: $295 · 2024: $324 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $246.83 | 2024-2025 | Clareon Panoptix Pro, Clareon |
| Sun Pharmaceutical Industries INC. | $236.01 | 2021-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $146.21 | 2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $131.02 | 2022-2023 | |
| Horizon Therapeutics Plc | $124.99 | 2021 | |
| Dompe US, INC. | $119.78 | 2024 | Oxervate |
| Spark Therapeutics, INC. | $114.75 | 2019 | |
| Astellas Pharma US INC | $86.46 | 2023 | Izervay |
| Abbvie INC. | $82.74 | 2024 | |
| Omeros Corporation | $78.81 | 2019 | |
| Rayner Intraocular Lenses Limited | $49.72 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.